GnRH analogues in the treatment of uterine fibroids.
نویسنده
چکیده
It is now known that gonadotrophin-releasing hormone analogues (GnRHa) are extremely efficient at reducing uterine fibroid volume and reversing the related symptomatology. However, the fibroids tend to return to their pretreatment size about 6 months after discontinuing treatment. GnRHa treatment cannot be continued indefinitely due to its potential complications and high cost. It is therefore proposed that GnRHa treatment should be phase one of a two-phase treatment plan for uterine fibroids. The initial course of GnRHa should be followed by either menopause or surgery. Experience with presurgical GnRHa use indicates a definite treatment advantage and the use of GnRHa as adjuncts to surgery is well established. The value of GnRHa treatment as a alternative to surgery in pre-menopausal patients, however, remains to be established.
منابع مشابه
Structure–activity relationship of GnRH ligands
Gonadotrophin-releasing hormone (GnRH) and its analogues are clinically valuable for the treatment of a variety of reproductive disorders including infertility, precocious puberty, uterine fibroids, endometriosis and polycystic ovarian disease, and have therapeutic value in the treatment of cancers of the prostate, breast, pancreas, ovary and pituitary (Conn and Crowley, 1991). Understanding of...
متن کاملUse of GnRH analogues pre-operatively for hysteroscopic resection of submucous fibroids: a systematic review and meta-analysis.
GnRH analogues are commonly used before hysteroscopic myomectomy to make surgery easier and safer, but they are expensive, have potential side effects and lack a robust evidence base to support this practice. We undertook a systematic review of the literature to determine whether, in women with submucous fibroids, pre-operative GnRH analogues were more effective than placebo/no treatment in ter...
متن کاملMRI characterization of uterine fibroids may predict success of GnRH agonist therapy prior to magnetic resonance focused ultrasound (MRgFUS) treatment
Background/introduction In managing women with large uterine fibroids, GnRH agonists can be used to reduce fibroid volume and decrease vascularity to enhance treatment outcomes with MRgFUS. GnRH agonists have been shown to reduce fibroid volume by as much as 30-40%. The purpose of this study was to examine the responsiveness of fibroids to pre-treatment with a GnRH agonist in relation to their ...
متن کاملI-46: Radiofrequency Ablation of Uterine Fibroids
Uterine fibroids are benign solid tumors that are present in the majority of women. While often asymptomatic, fibroids can result in abnormal uterine bleeding, pelvic pressure, pain, subfertility, dyspareunia and other symptoms. Submucous and intramural fibroids are most associated with heavy menstrual bleeding; subserosal fibroids are more often innocuous unless sufficiently large so as to con...
متن کاملBlood flow changes in the uterus induced by treatment with GnRH analogues.
The regulation of ovarian and uterine blood flow are important aspects of reproductive physiology. Rapid and profound alterations in the vasculature of the cycling ovary have been reported and suggestions that blood flow to individual follicles may play an instrumental role in the selection and maturation of the dominant follicle in the primate (Zeleznik etal, 1991). More recent data indicates ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
- Human reproduction
دوره 11 Suppl 3 شماره
صفحات -
تاریخ انتشار 1996